ABSTRACT
INTRODUCTION
Diclofenac and rofecoxib belong to the family of non-steroidal anti-inflammatory drugs (NSAIDs) or COX inhibitors. COX inhibitors are effective anti-inflammatory, antipyretic and analgesic agents, which are commonly used in the treatment of acute and chronic pain, rheumatoid arthritis and osteoarthritis. They act by inhibiting cyclo-oxygenase (COX) activity and consequently the formation of pro-inflammatory mediators like prostaglandins (PG) and thromboxanes (TXB) (1) . Since the early 1990s, it is generally accepted that cyclo-oxygenase exist in two isoforms. Cyclo-oxygenase-1 (COX-1) is a housekeeping enzyme responsible for modulating physiological events and is present in most tissues including the stomach, kidney and platelets, whereas cyclo-oxygenase-2 (COX-2) is highly induced in various cells by pro-inflammatory stimuli, mitogens and cytokines. Based on the IC 80 ratio obtained from the human whole blood assay (hWBA), diclofenac is a non-selective COX inhibitor, whilst rofecoxib is a highly selective COX-2 inhibitor (2).
Some COX inhibitors like diclofenac and rofecoxib are subject to enterohepatic recirculation (EHC) in animals (3) (4) (5) (6) (7) (8) . However, published reports have been of a descriptive nature, which restricts the extrapolation of findings to different experimental conditions. For instance, Baillie et al. refer to a secondary peak concentration following an i.v. bolus of rofecoxib in rats (2 mg kg -1 i.v. bolus), with T max at 10h after drug administration, whereas Peris-Ribera et al. have reported the same phenomenon after oral and i.v. administration of diclofenac, with Tmax values varying between 2 and 4 hours. In contrast to non-compartmental analysis, a model-based approach enables further characterisation of the influence of EHC on pharmacokinetic parameters such as bioavailability, clearance and terminal half-life. Moreover, integrated pharmacokinetic-pharmacodynamic (PK-PD) modelling can be used to investigate whether EHC-related changes in pharmacokinetics may consequently influence pharmacodynamic effects or increase the risk of side effects, such as gastrointestinal (GI) toxicity (9;10). In fact, it has been hypothesised that COX inhibitors that are not subject to EHC are less likely to produce intestinal damage (9) . Different methodologies have been developed to describe EHC in animals and humans (11) (12) (13) (14) (15) (16) . Of particular interest is the review by Roberts et al. (2002) which provides a detailed evaluation of enterohepatic recirculation concepts and models. They conclude that classical compartmental models with recycling loops are only suitable in the analysis of concentration-time profiles with a single secondary peak without large inter-and intra-individual variability. Moreover, rich sampling of pharmacokinetic data is required as input for the description of EHC, including data from portal and systemic concentrations (14) or from bile duct-cannulated animals (13) . An alternative to empirical models is the use of physiologically-based pharmacokinetic models. In fact, such an approach was proposed by Ploeger et al. (2000) to describe the kinetics of biliary excretion of glycyrrhizic acid. Also in this situation, the identification of relevant sources of variability remains limited. Noisy data with irregular patterns cannot be described by those models without a hierarchical component for random effects to which inter-individual variability can be assigned.
In early drug development, it is essential to accurately estimate drug clearance and concentration-effect relationships; as such information is required to subsequently predict the appropriate clinical dose range in humans. In most pre-clinical studies, drugs are initially administered as intravenous (i.v.) bolus and followed by oral (p.o.) dosing in a consecutive experiment. Usually, EHC and metabolite formation rates are ignored and no specific experiments are conducted to characterise their role on systemic kinetics. To date, despite the availability of non-linear mixed effects models for EHC in humans, no efforts have been made to characterise EHC in pre-clinical species which capture the appearance of multiple peaks and account for large inter-individual variability without the need for additional experiments. Therefore, the aim of this investigation was to develop and compare the performance of different pharmacokinetic models of EHC for diclofenac and rofecoxib in rats. The impact of variable metabolite formation rate due to EHC was explored with diclofenac by extending model parameterisation. In addition to the use of standard dummy compartments describing drug transfer across the GI tract, we have assessed the suitability of the recycling model proposed by Wajima et al. and the semi-parametric model based on constrained longitudinal splines (CLS) by . Furthermore, simulations were performed to evaluate the influence of EHC on the inhibition of PGE 2 , a biomarker for the pharmacodynamics of diclofenac and rofecoxib on COX-2 activity. Besides the advantages of nonlinear mixed effects, the proposed approach may warrant a reduction in the number of animals required for the investigation of EHC in pre-clinical species.
MATERIALS A AND M METHODS
The experimental part of this investigation consisted of two separate studies. One study was performed in The Netherlands for the assessment of the concentration-time profiles after i.v. administration of rofecoxib and i.p. administration of diclofenac and rofecoxib (study A). The second study was performed in the United Kingdom for the assessment of the concentration-time profiles after i.v. and oral administration of diclofenac and rofecoxib (study B). Data obtained from the different experiments were combined for the characterisation of EHC in rats by nonlinear mixed effects modelling.
Animals and surgical procedures Study A
Experiments were performed on male Sprague-Dawley rats (Charles River B.V., Maastricht, The Netherlands) weighting 331 ± 4 g (Mean ± stdev, n=6) for diclofenac and 320 ± 7 g (Mean ± SD, n=10) for rofecoxib and were approved by the Ethical Committee on Animal Experimentation of the University of Leiden. The animals were housed in standard plastic cages (six per cage before surgery and individually after surgery) with a normal 12-hour day/night schedule (lights on 7 AM) and a temperature of 21 0 C. The animals had access to standard laboratory chow (RMH-TM; Hope Farms, Woerden, The Netherlands) and acidified water ad libitum. Three days before the start of the experiment, indwelling pyrogen-free cannulae (Polythene, 14 cm, 
Study B
Experiments were performed on male Sprague-Dawley rats (Harlan, United Kingdom) weighting 297 ± 11 g (Mean ± stdev, n=3) for diclofenac and 245 ± 4 g (Mean ± stdev, n=3) for rofecoxib and were approved by the Ethical Committee on Animal Experimentation. The animals were housed in standard plastic cages (six per cage before surgery and individually after surgery) with a normal 12-hour day/night schedule (lights on 7 AM) and at a temperature of 21 0 C. The animals had access to standard laboratory chow and acidified water ad libitum. Three days before the start of the experiment, indwelling pyrogen-free cannulae (Polythene, 14 cm, The experiment was carried out on two study days with a wash-out period at least two days (>48 hours) between treatments. Drugs were administered intravenously on the first study day and orally on the second study day.
Drugs and dosages. For study A, rofecoxib was extracted from Vioxx® tablets (12.5 mg Vioxx ® Merck, Kirkland Quebec, Canada). Vioxx ® tablets were crushed to fine power, suspended in 50 ml of HPLC grade ethyl acetate, shaken for 5 minutes, and filtered. Residues were then crystallised from acetonitrile after evaporating the solvent in vacuum. During the extraction process, rofecoxib was protected from direct light to prevent degradation. The purity (97%) of rofecoxib was compared in triplicates to a pure sample of rofecoxib by LC-MSMS. Rofecoxib was dissolved in dimethylsulfoxide Experimental protocol. All experiments were started between 8.30 and 9.30 AM to exclude the influence of potential circadian variation in EHC. An infusion pump (Bioanalytical Systems Inc., Indiana, USA) was used for i.v. administration of diclofenac and rofecoxib. Per os administration was performed by oral gavage (5 ml kg -1 ). Serial arterial blood samples were taken at pre-defined time points and the total volume of blood samples was kept to 2.0 ml with volume replacement during each experiment. For study A, blood samples were heparinised and immediately centrifuged at 5000 rpm for 10 min for plasma collection and stored at -200C until analysis. For study B, blood samples were collected into tubes containing K 2 EDTA. Each sample was subsequently diluted with an equal volume of purified water and stored at -80 0 C until analysis.
Bioanalysis of diclofenac and its 4-hydroxy metabolite. For study A, concentrations of diclofenac were determined by HPLC with UV detection, as described by (20) The run time was of 20 min with the diclofenac peak at approximately 15 min and the flurbiprofen (IS, Sigma Aldrich, Dorset, UK) peak at approximately 10 min. The signal showed linearity over the range of 50-50000 ng ml -1 and the lower limit of quantification was 50 ng ml -1 . Bias and precision of the rat plasma calibration curves were assessed by quality control samples at nominal concentrations of 800 and 20000 ng ml -1 . Results were acceptable if variation in the measurements remained within 20% of the nominal concentration. The within-and between-day coefficients of variation of the assay were less than 10% and 20%, respectively.
For study B, diclofenac plasma samples (50 µl) were extracted using protein precipitation with acetonitrile:10 mM ammonium acetate (80:20) containing an internal standard (250 µl, 0.2 µg ml -1 ). An aliquot of the supernatant was analysed by reverse phase HPLC/MS/MS using a heat-assisted electrospray interface in positive ion mode. Nominal MRM transitions for diclofenac, its 4-hydroxy metabolite and internal standard (lumiracoxib) were 298 to 216 and 294 to 248, respectively. Samples (2 µl) were injected using a CTC Analytics HTS Pal autosampler (Presearch, Hitchin, UK) onto a Hypersil Aquastar 3.0 x 30 mm, 3-µm column (Thermo, Runcorn, Cheshire, UK) operated at 40 0 C and at an eluent flow rate of 1 ml min -1 . Analytes were eluted using a high-pressure linear gradient program, by means of an HP1100 binary HPLC system (Agilent, Stockport, Cheshire, UK), using 1mM ammonium acetate containing 0.1% (v/v) as solvent A and acetonitrile as solvent B. The gradient was held at 5% solvent B for 2 min, before increasing to 80% at 1.2 min, remaining at 80% until 1.6 min before returning to the starting conditions. The cycle time was 2.5 min per sample. An Aquastar column (30 x 3.0 mm, 3 µm id, Thermo, Runcorn, Cheshire, UK) was used for the chromatographic separation coupled to an API4000 tandem mass spectrometer (Applied Biosystems, Ontario). Samples were assayed in the range 5 to 5000 ng ml -1 and the lower limit of quantification was 2 ng ml -1 . Bias and precision of the rat plasma calibration curves were assessed with quality control samples (n = 6) at the following concentrations 5, 20, 2000 and 5000 ng ml -1 and results were accepted based on these quality controls being within 20% of the nominal expected concentration. The within-and between-day coefficients of variation of the assay were less than 8% and 10%, respectively.
Bioanalysis of rofecoxib. Rofecoxib plasma samples (50 µl) from study A and B were extracted using protein precipitation with acetonitrile:10 mM ammonium acetate (80:20) containing an internal standard (250 µl, 0.2 µg ml -1 ). An aliquot of the supernatant was analysed by reverse phase HPLC/MS/MS using a heat-assisted electrospray interface in negative ion mode. Nominal MRM transitions for rofecoxib and internal standard (celecoxib) were 313 to 284 and 380 to 316, respectively. Samples (5 µl) were injected using a CTC Analytics HTS Pal autosampler (Presearch, Hitchin, UK) onto a Supelco Discovery Cyano 4.6 x 50 mm, 5-µm column (Sigma-Adrich, Poole, Dorset, UK) operated at 40°C and at an eluent flow rate of 1 ml min 1. Analytes were eluted isocratically by means of an HP1100 binary HPLC system (Agilent, Stockport, Cheshire, UK), using 10 mM ammonium acetate containing 0.1% (v/v) as solvent A (50%) and acetonitrile as solvent B (50%). The cycle time was 2.2 min per sample. The eluent was injected into an API4000 tandem mass spectrometer (Applied Biosystems, Ontario). Rat plasma samples were assayed in the range 5 to 5000 ng ml -1 and the lower limit of quantification was 5 ng ml -1 . Bias and precision of the rat plasma calibration curves were assessed with quality control samples at the following concentrations, 5, 20, 2000 and 5000 µg ml -1 and results were accepted based on these quality controls being within 20% of the nominal expected concentration. Samples showing plasma concentrations above the upper limit of quantification were re-assayed by appropriate dilution in plasma to within the range of the calibration curve. The within-and between-day coefficients of variation of the assay were less than 10% and 10%, respectively.
Pharmacokinetic data analysis. The pharmacokinetics of diclofenac and rofecoxib was analysed using nonlinear mixed effects modelling as implemented in NONMEM version V, level 1.1 (21) . This approach allows the estimation of intra-individual as well as inter-individual variability in model parameters. All fitting procedures were performed on a computer (AMD-Athlon XP-M 3000+) running under Windows XP with the Fortran compiler Compaq Visual Fortran version 6.1. An inhouse available S-Plus 6.0 (Insightful Corp., Seattle, WA, USA) interface to NONMEM version V was used for data processing, data management and graphical data display. The first order conditional estimation method (FOCE) with interaction was used for fitting of the data. Model building details will be given for diclofenac first and complemented subsequently by specific requirements for rofecoxib. During model building, we have attempted to move from a fully empirical approach to a more physiologically meaningful parameterisation of EHC.
Structural model building. The pharmacokinetic analysis was performed using the ADVAN6 and ADVAN5 routine in NONMEM. Model selection was based on the likelihood ratio test, parameter point estimates and their respective confidence intervals, parameter correlations and goodness-of-fit plots. For the likelihood ratio test, the significance level was set at p=0.01, which corresponds to a decrease of 6.6 points, after the inclusion of one parameter, in the minimum value of the objective function (MVOF) under the assumption that the difference in MVOF between two nested models is χ 2 distributed. The following goodness-of-fit plots were subjected to visual inspection to detect (1) where frequency is the periodicity of recycling (which represented a cycle of enterohepatic circulation), which is constrained to be a divisor of 24 h.
The central compartment for the parent (compartment 2) and metabolite (compartment 4) is linked directly to the EHC compartment (compartment 3), through which the metabolite is also cleared from the systemic circulation. Subsequent uptake of either compound into the central compartment is described by the periodic transfer rate. It was assumed that all of the drug cleared into the EHC compartment remains bioavailable (F 3 ). The systemic disposition of diclofenac and 4-hydroxydiclofenac is described by separate compartments (compartment 5 and 7, respectively). Drug clearance was tested for parent and metabolite and elimination was determined on central In contrast to diclofenac, the pharmacokinetics of rofecoxib was highly variable and no concurrent metabolite data was available for an integrated pharmacokinetic analysis of parent drug and metabolite. The use of a model with a steady oscillatory behaviour was therefore not sufficient to describe in a semi-physiological manner the impact of EHC on systemic exposure, leading to parameter identifiability problems and model misspecifications. Hence, a slightly more complex model structure was proposed to describe EHC after administration of rofecoxib. Rofecoxib data were evaluated using one-, two -and three compartment models. These models were extended by a chain of compartments describing the transit of the drug from the central compartment to the gut and back. This chain constitutes a recycling loop with continuous transit and appeared sufficient for characterising EHC in animals without a gall bladder, such as rats. Despite the numerous attempts to account for and explain inter-individual variability, parameter estimates for the recycling loops could not be calculated. Model building was subsequently accomplished by adding a "conversion" compartment for the introduction of a delay, which allowed the estimation of a single first-order recirculation rate (k recycling ), reducing the number of parameters needed in the model ( figure 1.2 ).
Since metabolite concentrations were not available for this analysis, the appearance of parent drug derived from EHC into the central compartment was based on zero-order rate from a fictitious dose of into compartment 4. Furthermore, a mixture model was used to discriminate different populations in the data. Some rats displayed a clear secondary peak in their concentration-time profile whereas others displayed a plateau-phase (Figure 2 ). The algorithm identified two sub-populations with respect to the duration of the recycling process (D 4 ). Each individual was classified into a subpopulation of the mixture according to an empirical Bayesian computation, conditional on the individual's data and on the final estimates of the population parameters.
In order to corroborate the model estimates obtained for EHC and assess its contribution to the decrease in the total clearance of diclofenac and rofecoxib, published data from (3;22) in bile ductcannulated animals were reanalysed using the pharmacokinetic models proposed above with rate constants associated with the recycling compartment set to zero. This is equivalent to reducing the the appendix.
Stochastic model building. The stochastic part of the model was aimed at describing inter-individual variability in pharmacokinetics under the assumption of log-normal distribution of all population parameters. Therefore, an exponential model was used to account for inter-individual variability: (2) where θ is the population estimate for parameter P, P i is the individual estimate and η i is the normally distributed between-subject random variable with mean zero and variance ω 2 .
A model with a proportional error component was required to describe residual error in the plasma drug concentration:
where C obs,ij is the j th observed concentration in the i th individual, C pred,ij is the predicted concentration, and ε ij is the normally distributed residual random variable with mean zero and variance σ 2 . The residual error term contains the remaining random variability that cannot be explained by fixed effects and refers to measurement and experimental error (e.g. error in recording sampling times) and structural model misspecification.
Influence of EHC on pharmacodynamics
Simulations were performed to explore the relevance of EHC on pharmacodynamics using the 
where I 0 represents the baseline production of PGE 2 , which is assumed to 100%, I max the maximal response, which was set to 0.1% and n represents the Hill factor, with a value of 1, C D is the concentration of diclofenac and C 4-HD is the concentration of 4-hydroxydiclofenac. Based on in vitro data of diclofenac and 4-hydroxydiclofenac in whole blood assay (WBA), IC 50 values of 190 ng ml -1 and 1600 ng ml -1 , respectively, have been found for PGE 2 inhibition (24;25). Menasse et al. also suggest that the difference in potency between parent drug and metabolite is approximately 10-fold. Therefore, this ratio was used for the purpose of the simulations, i.e., IC 50 values of 190 and 1900 ng ml -1 for diclofenac and 4-hydroxydiclofenac, respectively. Data from bile ductcannulated animals were obtained from a publication by Tabata et al. (22) .
Since the metabolite of rofecoxib does not have pharmacological activity, the inhibition of PGE 2 was described by an inhibitory I max model: (5) where I 0 represents the baseline production of PGE 2, which is assumed to 100%, Imax the maximal response to diclofenac and rofecoxib, which was set to 0.1% and n the Hill factor, with a value of 1.
Based on in vitro data of rofecoxib in whole blood assay (WBA), an IC 50 value of 100 ng ml -1 was used for PGE 2 inhibition (8;26;27). Pharmacokinetic data from bile duct-cannulated animals were A summary of the population parameter estimates is shown in table 2. Fixed and random effects were estimated accurately, as indicated by the diagnostic procedures and by the estimates of variability.
The duration of the enterohepatic recycling process for rats with a second peak (sub-population 1) was 76 min and 336 min for rats with a plateau (sub-population 2). A large proportion of animals was assigned to sub-population 1 (P(1)=0.875, table 2). The estimate of 61% for inter-individual variability in the rate constant for enterohepatic recycling, k recycling , reveals large variation in this process despite the absence of gall bladder and periodic bile excretion pattern.
In addition to parameterising the recirculation process into an integrated pharmacokinetic model, data from bile duct-cannulated rats was used to substantiate the findings and estimate the contribution of EHC to changes in total clearance. Population estimates for clearance in these animals were 12 ml min -1 for diclofenac and 4.6 ml min -1 for rofecoxib. Using this information, the total transfer rate (i.e., clearance to the recycling compartment and central clearance) in rats with EHC 97 Table 1 
was calculated. The estimated parameter values were 6.2 ml min -1 for diclofenac and 4 ml min -1 for rofecoxib. For diclofenac, clearance to the recycling compartment was found to be as fast as the clearance from the central compartment, i.e., the rate constants k 23 is 0.857 min -1 versus k 20 is 0.728 min -1 . For rofecoxib it was not possible to estimate the rate transfer to the recycling compartment due to the large variability in the pharmacokinetic data. Based on the values for clearance, the absolute increase in drug exposure due to EHC has been calculated. The relevance of EHC to overall systemic exposure was assessed by estimating the ratio between CL bile duct cannulation / CL EHC , which was 1.95 and 1.15 for diclofenac and rofecoxib, respectively. For diclofenac EHC represents an increase of 95% in exposure (CL bile duct cannulation / CL EHC , whilst for rofecoxib this process corresponds to approximately 15% increase in total exposure, under assumption of first-order pharmacokinetics at the investigated dose range. These figures may vary considerably in the presence of nonlinear pharmacokinetics.
The final step in this investigation consisted in assessing the consequences of EHC for the antiinflammatory activity by simulations. The assessment of the effect of EHC on PGE 2 inhibition was based on total plasma concentration. The use of free concentration was deemed not necessary.
Model-predicted population parameter estimates were used to simulate concentrations of diclofenac 99 and rofecoxib over a period of 12 and 24 h, respectively. In figure 5 , the simulated pharmacokinetic profiles of diclofenac and 4-hydroxydiclofenac are displayed for rats with intact and cannulated bile duct. These results show that the maximum inhibition of PGE 2 in animals with cannulated bile duct is comparable to the values achieved in rats with intact EHC. However, the duration of inhibition is considerably shorter. At a dose of 10 mg kg -1 , inhibition due to EHC is prolonged for more than 16 hours. In contrast, maximum inhibition of PGE 2 following a dose of 1 mg kg -1 diclofenac is decreased in rats with intact EHC as compared to bile duct-cannulated animals. This difference can be assigned to the interaction between parent compound and metabolite, which is the 10-fold less potent than the parent compound. At higher doses, the contribution of 4-hydroxydiclofenac results in prolonged inhibition of PGE 2 .
In figure 6 , the simulated concentration time course of rofecoxib is displayed for both subpopulations in conjunction with the pharmacokinetic profiles after cannulation of the bile duct (3). Due to EHC, rofecoxib concentrations in plasma are almost 100-fold higher at 24 h post-dose, as compared to bile duct-cannulated animals. This difference results in a increase in the duration of drug effect on PGE 2 by more than 24 hours. From figure 6 , it is also clear that EHC does not have a significant effect on the maximum inhibition of PGE 2 .
DISCUSSION A AND C CONCLUSIONS
In the current study, we have assessed different parameterisations of the enterohepatic recirculation 100 Semi-parametric approaches, such as the constrained longitudinal spline (CLS) model have been proposed to analyse noisy data with large inter-individual variability and interpolate pharmacokinetic data (18;28) . This empirical method allows estimation of model-independent PK parameters such as t max , C max and AUC, without any assumption on the structural form of the kinetic model. Thus, parameter estimates derived from CLS are only influenced by the data and not by any prior assumption (28) . However, this approach is only suitable for interpolation and requires a balanced sampling design, which limits its use in drug development. Moreover, dose and route of administration have to be analysed independently, which reduces its statistical power. We have tested a series of CLS models with varying breakpoints in NONMEM (data not shown), but not all data sets resulted in a successful minimisation. Whilst one should try to increase sampling frequency in time 101 intervals where concentrations are changing the most, as in the case of the recirculation process, CLS models seem to perform better in the analysis of noisy sparse data (17) . Such a restriction adds up to the difficulties in finding a physiological interpretation for model parameters.
On the other hand, a mechanistic approach to pharmacokinetic modelling that incorporates EHC by measuring portal and systemic blood concentration differences have been developed for several drugs including diclofenac in rats (14;22;29) . Those models provide a scientific basis for the characterisation of the extent and rate of local drug absorption and disposition including EHC.
However, the use of such models is limited in pre-clinical drug development or standard PK/PD studies, as portal blood sampling is required. The parametric, semi-physiological approach presented in the current investigation to characterise EHC was developed taking into account the practical limitations and methodological issues discussed above. Our approach also illustrates the implication of nonlinear mixed effects modelling for accurate characterisation of pharmacokinetic processes in pre-clinical species, in that it enables concurrent analysis of data from different experimental settings.
Previous publications have shown that both diclofenac and rofecoxib are subject to EHC (3;6;13;30).
Our results show that the model proposed by Wajima et al. with a periodic transfer rate can describe the patterns of enterohepatic recirculation of diclofenac in rats. The approach was used initially to characterise single-subject profile in humans (19) . In addition, we have extended the model to analyse diclofenac and its metabolite, 4-hydroxydiclofenac concurrently. A separate disposition compartment was required to account for the contribution of 4 hydroxydiclofenac after oral and i.v.
dosing.
Despite the fairly variable pharmacokinetics of diclofenac, model parameters were estimated accurately, as indicated by the coefficients of variation (table 1) . Inter-individual variability (IIV) could be determined for k 20 , k 43 and k 45 . The latter parameter clearly reflects the varying pattern in the timing and magnitude of the secondary peaks that occur over time. The frequency parameter was estimated at 330 min after i.v., p.o. and i.p. administration, indicating that the recirculation process for diclofenac is not route dependent. The relative bioavailability after oral dosing was estimated at 72%, which is comparable to non-compartmental results by Peris-Ribera et al. who reported 79% (6) . We acknowledge that proposed model for diclofenac and its metabolite may appear physiologically unrealistic in that all of the drug in the EHC compartment can re-enter the central compartment. A model with separate compartments for bile, liver and GI tract and estimation of the bioavailable fraction from these compartments would provide a more physiological description the recycling process. However, such an attempt has resulted in model overparameterisation. An integrated analysis including experimental data from bile duct-cannulated rats is required to further characterise metabolite formation and recycling rate.
In contrast to diclofenac, rofecoxib data were not suitable for analysis by a compartmental model including an EHC compartment that transfers drug periodically into the central compartment. Due to large variability in a relative small data set, minimisation was unsuccessful for all tested models based on periodic transfer rates. Therefore, we have simplified the model by the addition of a socalled conversion compartment with first-order rate and a lag-time to account for EHC. A similar pharmacokinetic model was developed to describe EHC of ezetimibe in humans (12) . Model parameters were estimated accurately with acceptable values for the coefficients of variation (table   2) . Additional pharmacokinetic data are required to obtain more precise estimates of re-absorption process associated with EHC. Despite the limitations in the current data set, the use of nonlinear mixed effects modelling enabled identification of inter-individual variability in the recycling process, as indicated by k recycling , the re-absorption rate constant. Furthermore, implementation of a mixture model allowed the identification of two distinct sub-populations in the concentration vs.
time profiles of rofecoxib. The duration of the re-absorption was estimated to be 76 and 336 min in sub-population 1 and 2, respectively. Even though rats had limited access to food during the experiments, the identification of two sub-populations could be associated physiologically with food intake and differences in bile flow rate. The re-absorption rate parameter, k recycling was also tested as a mixture parameter, but no significant improvement was observed. The fraction of rofecoxib that was re-absorbed was estimated at 30%.
From a modelling perspective, our results illustrate that the concepts of periodic transfer rate and of a conversion compartment with first-order re-absorption offer a feasible alternative to characterising EHC in animals. However, this exercise would be incomplete without further consideration of two questions relevant to pre-clinical drug development, namely what is consequence of EHC to pharmacokinetics and pharmacodynamics and how to translate findings in animals to humans?
We have attempted to evaluate the aforementioned questions by looking at the change in clearance in the presence and absence of EHC and subsequently simulating drug response for a biomarker common to humans and rats, namely PGE 2 inhibition. The consequences of EHC to systemic exposure were assessed by estimating the ratio between CL bile duct cannulation / CL EHC , which was 1.95 and 1.15 for diclofenac and rofecoxib, respectively. For diclofenac, the increase in exposure due to EHC is significant and could have direct implications for the pharmacodynamic response. For rofecoxib, it may be claimed that due to EHC the dose of 10 mg kg -1 given intravenously becomes an effective dose of 11.5 mg kg -1 . However, this finding must be interpreted carefully, as for rofecoxib we have not been able to estimate the clearance to the central compartment. An extended model that includes this rate constant would be helpful to estimate the exact rofecoxib amount reaching the central compartment over time.
Our simulations to evaluate the impact of EHC on pharmacodynamics and potentially its meaning to scaling of data from animals to humans reveal that EHC can prolong the inhibition of PGE 2 .
However, EHC does not seem to affect the maximum PGE 2 inhibition. From the simulations with diclofenac, total PGE 2 inhibition in bile duct-cannulated rats was slightly higher than in rats with intact EHC, but such effect was short-lasting. This effect is reduced if one takes into account the contribution of the metabolite, which is 10-fold less potent than the parent compound.
Whilst drugs such as diclofenac and rofecoxib do exhibit significant EHC in humans, this pharmacokinetic phenomenon has often been identified at phase I clinical studies or even later in clinical development. Thus far, we are not aware of any research attempt aimed at describing EHC in a quantitative manner in animals. We have shown that modelling of EHC in pre-clinical species enables early prediction of the influence of EHC to pharmacokinetics and pharmacodynamics.
Prolonged exposure to drug as a consequence EHC may have serious implications, in particular when drug safety is a concern, as is the case for many NSAIDs.
In summary, we have shown that empirical and semi-physiological pharmacokinetic models can be used in conjunction with nonlinear mixed-effect modelling to characterise data with large interindividual variability. The approach allows concomitant analysis of data from different experimental sources, with fewer restrictions to frequency or intervals for sample collection. For diclofenac and its metabolite 4-hydroxydiclofenac:
d/dt(a1)=-k13*a1*f1 d/dt(a2)=-k20*a2-k23*a2+k32*a3*X(t)+k72*a7-k27*a2 d/dt(a3)= k63*a6*f6+k13*a1*f1+k23*a2+k43*a4-(k32+k34)*a3*X(t) d/dt(a4)=k54*a5-k45*a4-k40*a4-k43*a4+k34*a3*X(t) The delay in recycling was characterised by a lagtime for compartment 4.
Where k i,j are transfer rates, F 4 is the fraction of bioavailable rofecoxib that undergoes recycling, F 5 is the fraction of bioavailable rofecoxib after i.p. administration, F 6 is the fraction of bioavailable rofecoxib after p.o. administration, V 1 is the volume of the central plasma compartment of rofecoxib.
